Success Metrics

Clinical Success Rate
66.7%

Based on 6 completed trials

Completion Rate
67%(6/9)
Active Trials
0(0%)
Results Posted
100%(6 trials)
Terminated
3(30%)

Phase Distribution

Ph phase_2
6
60%
Ph phase_1
4
40%

Phase Distribution

4

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
4(40.0%)
Phase 2Efficacy & side effects
6(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(6)
Terminated(4)

Detailed Status

Completed6
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (40.0%)
Phase 26 (60.0%)

Trials by Status

completed660%
terminated330%
withdrawn110%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_1

A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients

NCT00363194
completedphase_1

A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors

NCT00678977
completedphase_1

A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors

NCT00722293
withdrawnphase_1

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

NCT01130623
completedphase_2

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

NCT01108055
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00363194Phase 1

A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients

Completed
NCT00678977Phase 1

A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors

Completed
NCT00722293Phase 1

A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors

Completed
NCT01130623Phase 1

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

Withdrawn
NCT01108055Phase 2

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Completed
NCT00430781Phase 2

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

Completed
NCT00549328Phase 2

Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer

Terminated
NCT01049776Phase 2

GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line

Terminated
NCT00945477Phase 2

Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade

Terminated
NCT00561795Phase 2

Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10